雄激素去势治疗早期心脏病风险增加

Cardiac Disease Incidence Rises Early After Starting Androgen Deprivation Therapy
雄雄激素去势治疗早期心脏病风险增加激素去势治疗早期心脏病风险增加雄激素去势治疗早期心脏病风险增加
NEW YORK (Reuters Health) Oct 26 - Among men with prostate cancer, treatment with androgen deprivation therapy (ADT) is associated with a higher incidence of heart disease within the first 12 months of treatment.
纽约（路透社卫生）10月26日---在前列腺癌患者中，雄激素去势治疗在前12个月的治疗中常伴随着心脏病的高发率。
Thus, men with low-risk prostate cancer who receive \"ADT for even a short duration may actually experience decreased overall survival as a result of this intervention,\" Dr. Christopher Saigal and co-authors warn in the October 1st issue of Cancer.
因此，低危的前列腺癌患者接受“甚至一段短期的持续雄激素去势治疗 可能实际上历经总体存活数的减少，这正是因为此干预而造成的 ”这一观点，此观点是Christopher Saigal博士和其同事在10月1日的《Cancer》上所告诫的。
Multiple lines of evidence - animal models, population-based and cross-sectional studies, and controlled clinical trials - support the association between androgens and cardiovascular health, the investigators note. This association is particularly relevant, the authors add, given the increasing use of hormonal therapy in prostate cancer
调查人指出：多方面的证据---动物模型，以人群为基础的和横断面研究，临床控制实验---支持雄激素和心血管健康之间的联系。考虑到在前列腺癌的治疗中使用雄激素的增加，作者补充到，此关联是显著性地相关。
To shed further light on these associations, Dr. Saigal, a urologist at the University of California at Los Angeles, and associates linked databases from the SEER national cancer registry and Medicare claims files. Study subjects were diagnosed with primary prostate cancer between 1992 and 1996 and followed for 5 years.
为了更明白清楚地显示这些关联，洛杉矶的一位加州大学的泌尿学家，Saigal博士，与其同事将流行病监督及最终结果资料库（SEER）的国家癌症注册信息的数据和医疗保险索赔文件联系起来，研究了那些在1992年和1996年之中的被诊断为前列腺癌早期的案例并追踪了5年。
The researchers identified nearly 23,000 subjects, among whom 21% received ADT. Treatment with ADT for at least 1 year was associated with a 20% higher risk of serious cardiovascular morbidity.
研究者们调查了将近23000个病患，其中21%的人接受过ADT，至少一年的ADT治疗与增加20%的心血管发病率是相关的。
\"These data have particular relevance to decisions regarding the use of ADT in men with prostate cancer in settings in which the benefit has not been clearly established,\" such as primary treatment in cases of localized prostate cancer, the investigators suggest.
研究者提出“这些数据对一些论断有着特殊的关联性，这些论断是关于在好处并未清楚地确定下来的这一背景下而对前列腺患者中施用ADT”,例如在非转移性前列腺癌中的初步处理。[color]
ADT is considered the \"mainstay of therapy\" among men with metastatic prostate cancer because it reduces cancer-related mortality, Dr. Saigal's group points out. Nevertheless, cardiovascular disease remains the most common cause of death among men with prostate cancer who do not die of their malignancy.
Saigal博士的团队指出，在转移性前列腺癌患者之中，ADT被认为是“中坚的疗法”，因为它降低了癌症相关的致死率。Saigal博士的团队指出：然而，在那些不会死于恶性肿瘤前列腺癌患者之中，心血管疾病仍然是最普遍的致死因素[color]
\"For men with metastatic disease, focused efforts to reduce cardiac risk factors through diet, exercise, or lipid-lowering agents may mitigate some of the risks of ADT,\" the investigators advise.
研究者建议“着眼于尽力通过饮食，锻炼或者降脂药来减小心脏风险因素，这样可能可以减少ADT的风险”.[